GlucoFend (Cinnamomum burmannii Extract)

GlucoFend is a proprietary extract of Cinnamomum burmannii, a cinnamon species containing cinnamaldehyde and A-type proanthocyanidins as its primary bioactive compounds. These constituents are theorized to influence insulin signaling pathways, though no clinical trials have been conducted on the GlucoFend branded extract specifically.

Origin & History

GlucoFend is a proprietary branded extract derived from Cinnamomum burmannii (Indonesian cinnamon), though no specific extraction methods or standardization details were identified in the research. The source material is typically the bark of C. burmannii, a tree native to Indonesia and Southeast Asia.

Historical & Cultural Context

No historical context specific to GlucoFend was found in the research. While C. burmannii has been used in Indonesian traditional medicine (Jamu) for digestion and metabolism, no details were provided in the search results.

Health Benefits

• No specific health benefits for GlucoFend were identified in peer-reviewed literature
• The research dossier yielded no clinical trials or studies on this branded ingredient
• General cinnamon research (not GlucoFend-specific) suggests mixed effects on fasting glucose in small trials
• No evidence quality can be assigned due to absence of GlucoFend-specific studies
• Manufacturer claims for glucose management remain unverified in the scientific literature

How It Works

Cinnamaldehyde, the predominant phenylpropanoid in Cinnamomum burmannii, is proposed to activate insulin receptor substrate-1 (IRS-1) phosphorylation and enhance GLUT4 transporter translocation to cell membranes, improving peripheral glucose uptake. A-type proanthocyanidins may inhibit intestinal alpha-glucosidase and alpha-amylase enzymes, slowing postprandial glucose absorption. Additionally, cinnamaldehyde has shown in vitro inhibition of protein tyrosine phosphatase 1B (PTP1B), an enzyme that negatively regulates insulin receptor signaling, though these mechanisms have not been confirmed for the GlucoFend extract specifically.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses specific to GlucoFend were found in the research. The search results focused on pharmaceutical glucose-lowering agents (PEG-loxenatide, lobeglitazone) with no mention of this cinnamon extract or relevant PMIDs.

Clinical Summary

No peer-reviewed clinical trials have been published on the GlucoFend branded extract of Cinnamomum burmannii. General research on Cinnamomum burmannii and related cinnamon species includes small randomized controlled trials, typically involving 30 to 90 participants over 8 to 12 weeks, showing modest and inconsistent reductions in fasting blood glucose ranging from 3% to 10% in some prediabetic cohorts. A 2013 meta-analysis of cinnamon species broadly found statistically significant but clinically modest fasting glucose reductions of approximately 8.2 mg/dL on average, with high heterogeneity across studies. The overall evidence base is considered preliminary, and results cannot be extrapolated directly to GlucoFend without extract-specific data.

Nutritional Profile

GlucoFend is a proprietary extract of Cinnamomum burmannii (Korintje/Indonesian cinnamon) bark, standardized for specific bioactive compounds rather than consumed as a whole food ingredient. As an extract, macronutrient content (fat, protein, carbohydrate) is negligible at typical supplemental doses (commonly 100–500 mg/day). Key bioactive compounds inherent to Cinnamomum burmannii bark include: (1) Cinnamaldehyde (trans-cinnamaldehyde): the principal volatile phenylpropanoid, typically comprising 55–90% of bark essential oil fraction; associated with insulin-mimetic activity in preclinical models. (2) Type-A Procyanidins (condensed tannins): polymeric polyphenols, particularly doubly-linked A-type linkages, reported at approximately 1–3% of dry bark weight in Cinnamomum species; these are the compounds most associated with glucose transporter (GLUT4) upregulation in cell studies. (3) Coumarin: present at notably higher concentrations in Cinnamomum burmannii compared to Ceylon cinnamon (C. verum), ranging from 1,000–12,000 mg/kg dry weight (vs. <10 mg/kg in C. verum); this represents a meaningful safety distinction, as the European Food Safety Authority (EFSA) tolerable daily intake is 0.1 mg/kg body weight. (4) Cinnamic acid and hydroxycinnamic acid derivatives: present at trace levels contributing antioxidant activity. (5) Eugenol: minor volatile phenol component, typically <5% of volatile fraction. (6) Minerals from whole bark: trace manganese (~1.5 mg/g dry bark), calcium, and iron, though extraction processes may reduce mineral content significantly. Bioavailability notes: cinnamaldehyde undergoes rapid first-pass metabolism to cinnamic acid; procyanidin bioavailability is limited by molecular size and gut microbiome-dependent breakdown; coumarin is well-absorbed orally and hepatotoxic at elevated exposures. No GlucoFend-specific standardization certificate or certificate of analysis has been identified in the public domain, so precise compound concentrations for this branded extract specifically remain undisclosed by the manufacturer.

Preparation & Dosage

No clinically studied dosages, forms, or standardization levels for GlucoFend were identified in the research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of GlucoFend-specific research

Safety & Interactions

Cinnamomum burmannii contains notably high levels of coumarin, a compound associated with hepatotoxicity at elevated intakes, distinguishing it from the lower-coumarin Ceylon cinnamon (Cinnamomum verum). Individuals taking insulin, metformin, or other hypoglycemic agents should exercise caution due to potential additive glucose-lowering effects that may cause hypoglycemia. Cinnamomum burmannii extracts are generally contraindicated during pregnancy at supplemental doses due to insufficient safety data and historical use as a uterine stimulant. Those with liver conditions or taking warfarin should consult a healthcare provider, as coumarin content may interact with anticoagulant metabolism via CYP2A6 pathways.